Botox Versus Tacrolimus in Psoriasis Vulgaris
ConditionPsoriasis Vulgaris
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-60
SponsorAssiut University
About this trial
Psoriasis is a systemic chronic relapsing immune-mediated disease which often requires a long-term therapy. Psoriasis occurs in around 2-3% of the total global population. In Egypt, the prevalence of psoriasis ranges between 0.19% and 3%.
Besides, it could have profound implications on the patients' psychological state and quality of life.
It is presented by erythematous, scaly plaques over the preferred sites. The pathogenesis of this highly complex disease is still far from being fully understood. Keratinocytes' hyperproliferation and immune system dysfunctions are well recognized contributors, with numerous treatments targeting these unique immunologic dysfunctions.
Eligibility criteria
Qualifiers
Patients with clinical diagnosis of mild to moderate psoriasis vulgaris
Patients who stopped any systemic therapy or phototherapy for at least 3 months and topical therapy for at least 4 weeks prior to enrollment.
Disqualifiers
• Psoriasis vulgaris involving > 10% of the body surface area, pustular or erythrodermic psoriasis.
Patients with neuromuscular disease or history of epilepsy.
Pregnant or lactating females.
Patients with any current dermatological disease.
Trial design
Treatments tested in this trial
- Botulinum Toxin-A
- Tacrolimus
Treatment groups
60 Participants
are divided into 3 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov